A highly sensitive indirect fluorescence antibody test (IFAT) has been developed on the basis of varicella-zoster virus (VZV)-infected human lung carcinoma (A549) cells and evaluated for the determination of immunity to VZV. Different serum panels with negative, low, moderate or high anti-VZV IgG levels detected by the fluorescent antibody to membrane antigen (FAMA) assay were investigated. As a result, the sensitivity and the specificity of IFAT were 100% compared to FAMA test. In anti-VZV IgG-positive sera, a significant correlation between the results of FAMA procedure and IFAT could be shown. However, there were considerably higher antibody titers by the IFAT than by FAMA. Whereas the FAMA test had a detection limit of 250 mIU/ml anti-VZV IgG, the limit of detection of IFAT was 50 mIU/ml. In conclusion, the IFAT using VZV-infected A549 cells as antigen allows a highly sensitive, specific, and rapid detection of anti-VZV IgG class antibodies. This simple technique can replace the labor-intensive FAMA procedure for laboratory determination of immunity to VZV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jviromet.2004.02.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity and Safety of the Recombinant Adjuvanted Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia and Multiple Myeloma.
Vaccines (Basel)
October 2024
School of Health Sciences, Faculty of Medicine, Hematology Division, University of Patras, 26504 Patras, Greece.
Background/objectives: Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are susceptible to viral infections, including varicella-zoster virus (VZV) reactivation due to both disease-related and treatment-induced immunosuppression. The recombinant adjuvanted herpes zoster vaccine (RZV) has shown high efficacy in immunocompetent adults, but immunogenicity data in CLL and MM patients are limited. This study evaluates the immunogenicity and safety of RZV in this population.
View Article and Find Full Text PDFStructures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited Antibodies.
Vaccines (Basel)
September 2024
GSK, Rockville, MD 20850, USA.
Varicella zoster virus (VZV) is the causative agent for chickenpox and herpes zoster (HZ, shingles). HZ is a debilitating disease affecting elderly and immunocompromised populations. Glycoprotein E (gE) is indispensable for viral replication and cell-to-cell spread and is the primary target for anti-VZV antibodies.
View Article and Find Full Text PDFSeroprevalence Assessment of Anti-Varicella Antibodies among Adults in the Province of Florence (Italy).
Vaccines (Basel)
September 2024
Department of Health Sciences, University of Florence, 50134 Florence, Italy.
Article Synopsis
- Around 90% of varicella (chickenpox) infections are mild, but adults can experience more severe cases, prompting a study in Florence, Italy, to assess immunity levels post-vaccination.
- A survey of 430 adults (ages 18-94) showed that 89.5% tested positive for varicella antibodies, with no significant differences based on sex or nationality.
- The findings indicated that while vaccination efforts have improved immunity, there is still a notable susceptibility (11.6%) among women aged 18-49, emphasizing the need for ongoing vaccination campaigns and awareness.
Challenges in Diagnosing Varicella-Zoster Virus Encephalitis in an Immunocompromised Patient.
Cureus
July 2024
Internal Medicine, St. Bernardine Medical Center, San Bernardino, USA.
Varicella-zoster virus (VZV) is a virus of the alphaherpesvirus family that is one of the common causes of infectious encephalitis worldwide, especially among those who are immunocompromised. In this case report, we discuss a case of a 55-year-old female with end-stage renal disease presenting with altered mental status and weakness. She was recently diagnosed with herpes zoster on oral acyclovir and multiple scattered dermatomal rashes on presentation.
View Article and Find Full Text PDFReplication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon.
J Infect
October 2024
Centre de Recherches Médicales de Lambaréné, CERMEL, Lambaréné, Gabon; Institute of Tropical Medicine, Travel Medicine and Human Parasitology, Competence Centre for Tropical Medicine Baden-Württemberg, Universitätsklinikum Tübingen, Tübingen, Germany; German Center for Infectious Diseases Research (DZIF), Tübingen, Germany; Institute of Medical Microbiology, University Hospital Münster, Münster, Germany. Electronic address:
Background: Unlike adults, children experienced stronger and longer vector replication in plasma and shedding in saliva following rVSVΔG-ZEBOV-GP vaccination. The resulting risks of immunosuppression or immune hyperactivation leading to increased Adverse Events (AEs) and altered antibody responses are concerns that have been addressed in the present manuscript.
Methods: Children aged 1-12 years living in Gabon received either rVSVΔG-ZEBOV-GP (ERVEBO®) vaccine or the varicella-zoster virus (VZV) vaccine (VZV).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!